Dual-payload ADCs are gaining traction, offering opportunities to overcome the tumour heterogeneity and resistance challenges faced by conventional ADCs.
Breakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback